NUMA1 and urinary bladder neoplasm: Numerous urine biomarkers such as nuclear matrix protein 22 NMP22 (Matritech, Newton, MA, USA), bladder tumor antigen BTA Stat and TRAK tests (Bard Diagnostic Sciences, Redmond, WA, USA), UroVysion (Vysis-Abbot Laboratories, Downers Grove, IL, USA) and ImmunoCyt/uCyt+ (DiagnoCure Inc., Saint-Foy, QC, Canada) have received European Medicines Agency (EMA) and Food and Drug Administration (FDA) approval for BCa diagnosis and surveillance.